Based on these findings and given that MM cells express high levels of Mcl-1 and its expression level determines clinical outcome10,38, we evaluated AZD5991 for its efficacy against growth of MOLP-8 tumors in vivo. This evidence concerns the gene MCL1 and Miyoshi myopathy.